Shots:

• The P-III study involves assessing JTA-004 (enhanced viscosupplement) vs PBO and the active comparator to reduce pain measured by the WOMAC pain subscale in patients with osteoarthritic pain in the knee
• The study showed that all treatment arms have similar efficacy- no significant difference in knee pain reduction b/w JTA-004- PBO- and active comparator @3mos. after treatment. JTA-004 have a favorable safety profile like PBO and comparator
• The company is focusing on the development of its core assets- the allogeneic cell therapy platform- including ALLOB- which is currently being evaluated in a P-IIb study in 178 patients with fresh tibial fractures at risk of delayed or non-union

  | Ref: Globe Newswire | Image: Ortho Spine News